DYRK1A and Dravet syndrome: The mechanisms that mediate the multitude of pathological consequences of an increased DYRK1A dosage in the brain of DS patients may involve deregulation of the cell cycle (discussed below), impaired neuronal differentiation and cell death, a precocious onset of neurogenesis and the concomitant depletion of the proliferating progenitors, and abnormal neuronal migration, transport, or synaptic function (reviewed in (Tejedor and Hammerle, 2011; Arbones et al., 2019; Kurabayashi et al., 2019; Atas-Ozcan et al., 2021)).